Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Virtual Clinical Trials: Perspectives in Dermatology

    Research output: Contribution to journalReviewResearchpeer-review

  3. Socioeconomic Costs and Health Inequalities from Psoriasis: A Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Bariatric surgery and risk of new-onset inflammatory bowel disease: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased all-cause mortality in concomitant atopic dermatitis and asthma: A nationwide registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The epidemiology and burden og psoriasis

    Research output: Book/ReportDoctoral thesis

View graph of relations

BACKGROUND: Wide fluctuations in placebo responses have been reported in phase 3 trials of systemic therapies for moderate-to-severe plaque psoriasis.

METHODS: In this systematic review and meta-analysis, we assessed placebo responses in phase 3 trials of systemic therapies for moderate-to-severe plaque psoriasis. The medical databases PubMed Medline, Embase, and Web of Science were searched for studies reporting on phase 3 psoriasis trials. A proportion meta-analysis determined the proportion of placebo-treated psoriasis patients obtaining a 75, 90, or 100% reduction in Psoriasis Area and Severity Index (PASI), that is, PASI75, PASI90, or PASI100, respectively, at week 12. In the assessment of PASI75 response, 44 trials with a total number of 7,972 patients were included.

CONCLUSION: In pooled analyses, 5.2% (95% CI 4.7-5.7%) obtained PASI75, 2.1% (95% CI 1.7-2.4%) obtained PASI90, and 0.3% (95% CI 0.1-0.5%) obtained PASI100 among placebo receivers. No temporal changes were observed. The overall proportion of placebo responders in phase 3 psoriasis trials is low and does not appear to be increasing in recent years.

Original languageEnglish
JournalDermatology
Volume237
Issue number2
Pages (from-to)158-165
Number of pages8
ISSN1018-8665
DOIs
Publication statusPublished - Mar 2021

ID: 67626121